Key Points
- KalVista Pharmaceuticals insider Nicole Sweeny sold 1,489 shares on May 26 at an average price of $26.78, for proceeds of about $39,875. The sale reduced her ownership by 2.45% and was made to cover tax withholding tied to equity award vesting.
- Sweeny has been active in the stock recently, also selling 1,861 shares on May 22 and 1,862 shares on April 17, all at prices around the mid-$20 range or lower.
- The company’s stock has been near its 52-week high, opening at $26.79 with a market cap of $1.43 billion, while KalVista recently reported a smaller-than-expected quarterly loss and analysts currently rate the stock a consensus Hold with a $30.60 price target.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Nicole Sweeny sold 1,489 shares of the company's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the transaction, the insider directly owned 59,291 shares in the company, valued at approximately $1,587,812.98. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Nicole Sweeny also recently made the following trade(s):
- On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $26.78, for a total value of $49,837.58.
- On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total value of $37,649.64.
KalVista Pharmaceuticals Stock Performance
Shares of NASDAQ KALV opened at $26.79 on Thursday. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The stock's fifty day moving average price is $21.94 and its two-hundred day moving average price is $17.65. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million during the quarter, compared to the consensus estimate of $39.03 million. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. Stifel Nicolaus increased their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Citizens Jmp lowered KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. Leerink Partners lowered KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. JonesTrading lowered KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $30.60.
Check Out Our Latest Analysis on KalVista Pharmaceuticals
Hedge Funds Weigh In On KalVista Pharmaceuticals
Several large investors have recently bought and sold shares of KALV. Tudor Investment Corp ET AL bought a new position in KalVista Pharmaceuticals in the third quarter valued at about $24,360,000. Vestal Point Capital LP raised its position in KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company's stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company's stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. raised its position in KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company's stock valued at $10,685,000 after purchasing an additional 905,053 shares during the last quarter. Finally, Elmind Capital LP bought a new position in KalVista Pharmaceuticals in the fourth quarter valued at about $12,941,000.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
